certain recombinant TRAIL preparations were cytotoxic
systemic immunoregulatory impact of the intracister-
Mann-Whitney U test). After disease peak, the mean total number of infiltrating cells per mouse (±SEM) was nally applied DR5:Fc, as previously shown by others (Hilliard et al., 2001) . Therefore, we recovered T cells 2.0 × 10 6 ± 0.8 for Fc-treated animals (n = 6) and 2.5 × 10 6 ± 1.1 for DR5:Fc-treated animals (n = 5; p > 0.05, and macrophages/microglia cells from the brains of SJL animals transferred with encephalitogenic T cells Mann-Whitney U test). In a similar experiment, CNSdraining deep cervical lymph node cells, as well as and treated with three intracisternal injections of DR5:Fc or Fc alone. We found that, at the very onset of splenocytes, were isolated at day 11 posttransfer and checked for antigen-specific proliferation and cytokine the disease (day 7 posttransfer), in the DR5:Fc-treated animals even more T cells expressed the activation profiles (IFN-γ and IL-4). However, analysis of these parameters revealed neither a systemic effect of marker CD25 (Figure 2A ). After the peak of the disease, no differences in the activity of the T cells were further DR5:Fc treatment on lymphocyte proliferation nor cytokine synthesis in lymphocytes from deep lymph observed. Absolute numbers and proportion of T cells and macrophages/microglia cells were comparable at nodes or in splenocytes ( Figure 2B ). We next investigated the body distribution of intracisternally applied both time points: at disease onset, the mean total number of infiltrating cells per mouse (± SEM) was 3.2 × DR5:Fc. This was possible by detection of the human Fc fragment contained in this recombinant molecule. 10 6 ± 1.6 for Fc-treated animals and 2.7 × 10 6 ± 1.4 for DR5:Fc-treated animals (n = 4 for both groups; p > 0.05, We found this fusion protein diffusely distributed in the sooner than 6 hr, we found DR5:Fc-containing macrophage-like cells prominently in the spleen ( Figure 2C In contrast, apoptotic neurons in normal control mice tions of recombinant preparations of multimerized human TRAIL induced neither clinical disability nor apoptosis of were entirely absent. Our immunohistochemical analysis of normal mouse brain showed expression of the neurons and oligodendrocytes, respectively, in healthy SJL mice ( Figure 6A ). In contrast, the same TRAIL prepdeath-mediating TRAIL receptor 2 predominantly on neurons and, to some extent, on oligodendrocytes (Figarations were effective in killing mouse fibroblasts (O.A. and F.Z., unpublished data). We therefore assumed that ures 5A-5D). Importantly, in the course of EAE, we detected TRAIL-positive lymphocytes that had invaded susceptibility to TRAIL-mediated cell death is differentithe brain in close vicinity and direct contact with neually regulated in normal and inflamed murine brain tisrons showing the appearance of caspase 3 activation sue. Supporting this idea, quantitative gene expression in their cytoplasm (Figures 4F and 4G ). These data suganalysis showed that both the death-mediating TRAIL gest that brain-infiltrating and TRAIL-expressing lymphoreceptor 2 and TRAIL itself are significantly upregulated cytes are able to deliver an apoptosis-inducing signal to in the CNS during EAE (Figures 6B and 6D) . 
test). (C) TRAIL mRNA expression was detected in MOG-specific T cells from wild-type animals but not in TRAIL-deficient T cells. Number of PIpositive cells (means with SEM) is demonstrated in the neuronal cell layer of CA and DG after invasion of wild-type or TRAIL-deficient MOGreactive lymphocytes (*p < 0.05, Mann-Whitney U test). (D) With confocal laser scanning microscopy, TRAIL expression (blue) is demonstrated by fluorescence labeling of fixed and permeabilized encephalitogenic T cells using a wide pinhole and aperture for detection (left panel). After invasion into brain tissue (right panel), CFDAlabeled T cells (green) were found adjacent to dead PI-stained neuronal nuclei (red) surrounded and contacted by secreted TRAIL (blue). Areas without T cells and neurons do not contain any labeling for TRAIL (circles). Scale bars, 10 m.
compared to injection of the enhancer alone, applicalitogenic lymphocytes in living organotypic brain slices.
PLP-specific activated lymphocytes used to induce tion of TRAIL prior to and at the onset of EAE significantly increased EAE severity [Figures 6E and 6F;
transfer EAE were stained with carboxyfluorescein diacetate (CFDA) and applied to the surface of these ., 2003) . In the present study, we employed strategies for a selective blockade of activated TRAIL-deficient lymphocytes from knockout TRAIL within the CNS, which is an anatomically and animals showed a significant reduction in their killing immunologically separate compartment. In fact, in concapacity. Using 2-photon laser scanning microscopy trast to systemic application of soluble TRAIL receptor for live imaging in slices (Nitsch et al., 2004) , we remolecules outside the brain (Hilliard et al., 2001) , cently observed that TRAIL-deficient T cells directly DR5:Fc injection selectively into this compartment recontact neurons but show a reduced neurotoxic capacsulted in an amelioration of EAE. We were able to show ity (O.A., E.P., R.N., and F.Z., unpublished data). Morethat our intracisternal route of injection did not influover, functional blockade of TRAIL using DR5:Fc was ence the peripheral immune response including T cell effective in preventing this neuronal cell death, indicatproliferation and cytokine release. Furthermore, transfer ing a pivotal role of TRAIL in damage processes. Howof myelin-specific TRAIL-deficient T cells into wild-type ever, it is possible that TRAIL secreted by infiltrating recipients yielded a significantly attenuated disease macrophages may contribute to TRAIL-mediated neuscore. In this experimental setting, the peripheral imral damage in EAE, as we recently identified activated munomodulatory role of TRAIL was preserved, as remacrophages as a significant source of soluble TRAIL cipient wild-type animals were still able to regulate the 
